国际肿瘤学杂志最新文献

{"title":"Expression and clinical significance of ribosome-binding protein 1 in esophageal carcinoma","authors":"Peng Yancai, Hao Dengrong","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.11.005","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.11.005","url":null,"abstract":"Objective \u0000To investigate the expression and clinical significance of ribosome-binding protein 1 (RRBP1) in esophageal carcinoma. \u0000 \u0000 \u0000Methods \u0000A total of 120 esophageal carcinoma patients admitted to Yulin First Hospital of Shaanxi Province from January 2010 to December 2014 were enrolled in this study. RRBP1 expression was detected in esophageal carcinoma and matched adjacent normal tissues by real-time quantitative PCR (qRT-PCR), Western blotting and immunohistochemical staining. The relationships of RRBP1 expression with clinicopathological futures and prognosis were statistically analyzed. \u0000 \u0000 \u0000Results \u0000RRBP1 expression level was significantly higher in esophageal carcinoma tissues compared with matched adjacent normal tissues. In the mRNA level, the relative quantitative expression in tumor tissues was 3.5±1.3, and 1.0±0.3 in adjacent normal tissues, with a significant difference (t=19.130, P<0.001). In the protein level, the relative quantitative expression in tumor tissues was 1.0±0.4, and 0.3±0.1 in adjacent normal tissues, with a significant difference (t=4.225, P<0.001). The immunohistochemical results showed that RRBP1 high expression was found in 71 (59.2%) tumor tissues, and the proportion dropped to 11.7% (14/120) in adjacent normal tissues, with a significant difference (χ2=59.182, P<0.001). In addition, RRBP1 expression was correlated with lymph node metastasis and TNM stage (χ2=10.631, P=0.001; χ2=31.212, P<0.001). Survival analysis revealed that RRBP1 expression, lymph node metastasis and TNM stage were significantly correlated with patients′ prognosis (χ2=9.455, P=0.006; χ2=14.542, P<0.001; χ2=11.987, P<0.001). Cox regression analysis showed that high expression of RRBP1 (RR=2.441, 95%CI: 1.267-4.702, P=0.008), lymph node metastasis (RR=4.024, 95%CI: 2.180-7.424, P<0.001) and high TNM stage (RR=3.054, 95%CI: 1.452-6.421, P=0.003) were the risk factors for poor prognosis of esophageal carcinoma patients. \u0000 \u0000 \u0000Conclusion \u0000RRBP1 is highly expressed in esophageal carcinoma and can serve as a potential biomarker to predict patients′ prognosis. \u0000 \u0000 \u0000Key words: \u0000Esophageal neoplasms; Prognosis; Survival analysis; Ribosome-binding protein 1","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"11 1","pages":"668-672"},"PeriodicalIF":0.0,"publicationDate":"2019-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85692836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research advances of EDIL3 in tumor","authors":"Ke Bin, Li Bin, Liang Han","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.11.007","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.11.007","url":null,"abstract":"Epidermal growth factor (EGF)-like repeat and discoidin Ⅰ-like domain 3 (EDIL3) is a extracellular matrix protein that produced and secreted by endothelial cells and plays important roles in embryonic development, angiogenesis, and limit inflammation. Several recent studies indicate that EDIL3 is aberrantly expressed in pancreatic cancer, liver cancer, colorectal cancer, lung cancer and breast cancer, which is associated with cell proliferation, apoptosis, invasion, metastasis, and angiogenesis. EDIL3 is widely participated in the regulating tumor initiation, progression and metastasis, and its abnormal expression is expected to provide a new method for diagnosis and therapy of cancers. \u0000 \u0000 \u0000Key words: \u0000Neoplasms; Angiogenesis; Apoptosis; EGF-like repeat and discoidin Ⅰ-like domain 3","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"74 1","pages":"678-681"},"PeriodicalIF":0.0,"publicationDate":"2019-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78150593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanism of RhoA in malignant tumors","authors":"Sun Guangshun, Mei Jie, Z. Meng, Wu Di, Pan Jia-dong, Liu Xiao","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.11.009","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.11.009","url":null,"abstract":"As a representative member of the Rho family, RhoA plays an important role in the oncogenesis and development of malignant tumors. According to previous studies, RhoA functions as a key regulator in mediating actin polymerization, cytoskeletal structure remodeling, cell polarity changes, epithelial-mesenchymal transition and so on. RhoA can promote multiple malignant phenotypes of tumor cells, such as migration, invasion, etc. At present, mainstream research believes that RhoA functions as oncogene in the carcinogenesis of tumors. Downregulated RhoA can inhibit tumor growth and progression, which can be used as a potential target for clinical anti-tumor therapy. \u0000 \u0000 \u0000Key words: \u0000Neoplasms; Neoplasm metastasis; Cytoskeleton; RhoA","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"1 1","pages":"686-691"},"PeriodicalIF":0.0,"publicationDate":"2019-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91147042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of 3D-CRT combined with PC chemotherapy on non-small cell lung cancer patients and serum CA125, TIMP-1, SAA levels and immune function","authors":"胡文铧 陈华林 林炯 赖振南 梁亚海 吴爱兵 杨志雄 王永存","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.11.004","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.11.004","url":null,"abstract":"Objective \u0000To investigate the effect of three-dimensional conformal radiotherapy (3D-CRT) combined with PC chemotherapy (paclitaxel + carboplatin) on non-small cell lung cancer (NSCLC) patients and the serum levels of CA125, tissue inhibitor of metalloproteinase-1 (TIMP-1), serum amyloid A (SAA) and T-lymphocyte subsets. \u0000 \u0000 \u0000Methods \u0000A total of 100 patients with NSCLC treated in Affiliated Hospital of Guangdong Medical University from May 2015 to December 2017 were selected as the study subjects. They were divided into control group and observation group according to random number table method, with 50 cases in each group. The observation group was treated with 3D-CRT combined with PC chemotherapy, while the control group was treated with PC chemotherapy. The two groups were treated for 4 cycles. The therapeutic effect, serum CA125, TIMP-1, SAA, T-lymphocyte subsets and adverse reactions were compared between the two groups. \u0000 \u0000 \u0000Results \u0000Four cases were lost to follow-up both in the two groups. The overall response rate in the observation group (43.48%, 20/46) was higher than that in the control group (23.91%, 11/46; χ2=3.941, P=0.047). The serum levels of CA125, TIMP-1 and SAA of the two groups had no significant difference before treatment, and the levels of these indexes decreased after treatment. The serum levels of CA125, TIMP-1 and SAA in the observation group after treatment were (12.31±1.13) U/ml, (275.31±13.69) pg/ml and (47.21±7.21) mg/L, which were lower than those in the control group [(30.36±1.98) U/ml, (320.36±17.23) pg/ml, (65.92±8.36) mg/L], with significant differences (t=53.699, P 0.999], abnormal liver function [6.52% (3/46) vs. 2.17% (1/46); χ2=0.261, P=0.609] and myelosuppression [8.70% (4/46) vs. 6.52% (3/46); χ2=0.000, P>0.999] between the observation group and the control group. \u0000 \u0000 \u0000Conclusion \u0000For patients with NSCLC, 3D-CRT combined with PC chemotherapy can improve the overall response rate, decrease the levels of serum CA125, TIMP-1 and SAA, and improve the immune function of patients. The therapeutic effect is remarkable and the safety is good. The therapeutic scheme is suitable for the treatment of NSCLC. \u0000 \u0000 \u0000Key words: \u0000Carcinoma, non-small-cell lung; Drug therapy; Three-dimensional conformal radiotherapy; Tissue inhibitor of metalloproteinase-1","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"56 1","pages":"662-667"},"PeriodicalIF":0.0,"publicationDate":"2019-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88429605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MYC inhibition associated mechanism research of Group3 medulloblastoma","authors":"Xilin Yang, Xiaoping Chen","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.10.009","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.10.009","url":null,"abstract":"Medulloblastoma (MB) is the most prevalent pediatric brain tumor. Group3 MB is the most malignant subgroup, quiet a part of which are MYC-amplified. Blocking the upstream gene sites of MYC is mainly achieved through the blockade of miR-494, DDX3, NOTCH1 pathway; BETi or ATR/Chk1 double-inhibition realizes the inhibition of duplication or transcription of MYC; as to the blockade of downstream genes of MYC, researchers mainly focus on LDHA, SETD8 and EZH2. All of these researches which target on MYC-amplified associated anti-tumor treatment mechanism present the theoretical basis for anti-MYC-associated medulloblastoma clinically. \u0000 \u0000Key words: \u0000Medulloblastoma; Genes, MYC; Group3; Treatment mechanism","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"252 1","pages":"613-616"},"PeriodicalIF":0.0,"publicationDate":"2019-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73141904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of leukemia inhibitory factor in tumorigenesis and development","authors":"Sainyu Si, Huaying Wang, Wanjun Yu, Jipeng Li","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.10.007","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.10.007","url":null,"abstract":"Leukemia inhibitory factor (LIF) is a multifunctional secretory cytokine that plays a role in different tumor tissues and cells through janus kinase/signal transducer and activator of transcription 3, phosphatidylinositol 3-kinase, mitogen-activated protein kinase signaling pathways. LIF is highly expressed in colo-rectal cancer, breast cancer, malignant melanoma, nasopharyngeal carcinoma and other malignant tumors. High expression of LIF can promote the development of cancer, increase the ability of tumor invasion and migration, reduce the sensitivity of radiotherapy and chemotherapy, and lead to poor prognosis. Blocking the LIF signaling pathway can inhibit tumor progression, and LIF is expected to become a new target for tumor therapy. \u0000 \u0000Key words: \u0000Neoplasms; Leukemia inhibitory factor; STAT3 transcription factor","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"3 1","pages":"605-608"},"PeriodicalIF":0.0,"publicationDate":"2019-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82524195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New progress of cabozantinib in the treatment of metastatic renal cell carcinoma","authors":"Yan Mei, Yizhou Zhao","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.10.014","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.10.014","url":null,"abstract":"Renal cell carcinoma (RCC), the most common form of kidney cancer, is characteristic by difficult in diagnosis at an early stage, insensitivity to chemoradiotherapy, poor prognosis, etc.. Localized RCC is treated by surgery while advanced RCC is mainly treated by immunotherapy and targeted therapy. With the ongoing in-depth researches on targeted therapy in recent years, plenty of targeted drugs come into the market in succession. Cabozantinib has been approved for the treatment of advanced RCC in the first/second line setting. It′s safety profile and efficiency have been demonstrated in Ⅱ-Ⅲ clinical trials. \u0000 \u0000Key words: \u0000Carcinoma, renal cell; Clinical trial; Cabozantinib","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"1 1","pages":"631-633"},"PeriodicalIF":0.0,"publicationDate":"2019-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84020195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of stereotactic body radiation therapy in advanced renal cell carcinoma","authors":"Liang Cai, Yali Shen","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.10.013","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.10.013","url":null,"abstract":"Stereotactic body radiation therapy (SBRT) can effectively kill renal cancer cells by biological molecules such as hypoxia-inducible factor-1α and acid sphingomyelinase. SBRT regimen with higher biological dose and single irradiation can achieve more effective local control of primary and metastatic lesion of advanced renal cancer, and adverse reactions can be tolerated. Combination of SBRT and targeted drugs can increase the sensitivity of renal cancer to radiotherapy, and the combination of SBRT and immune drugs can enhance the immune response through the abscopal effect. The efficacy of SBRT in the treatment of advanced renal cancer remains to be explored. \u0000 \u0000Key words: \u0000Kidney neoplasms; Advanced tumor; Stereotactic body radiation therapy","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"1 1","pages":"627-630"},"PeriodicalIF":0.0,"publicationDate":"2019-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82327737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer","authors":"Qiuping Mo, Yiding Chen, Xiaochen Wang","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.10.010","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.10.010","url":null,"abstract":"With roles of blocking cell proliferation, cyclin-dependent protein kinase (CDK) 4/6 inhi-bitors are effective and safe complementary therapies for hormone receptor-positive breast cancer. CDK4/6 inhibitors combined with endocrine therapy significantly improve the prognosis of patients with advanced or metastatic breast cancer, especially those with endocrine resistance. Indications for CDK4/6 inhibitors are also expected to broaden into early-stage breast cancer. However, mechanisms of resistance of CDK4/6 inhibitors remain elusive. \u0000 \u0000Key words: \u0000Breast neoplasms; Receptors, estrogen; Cyclin-dependent kinases; Therapeutics","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"6 1","pages":"617-619"},"PeriodicalIF":0.0,"publicationDate":"2019-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80548622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human telomerase reverse transcriptase and cutaneous malignant tumor","authors":"Juan Zhao, X. Kang","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.10.015","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.10.015","url":null,"abstract":"Human telomerase reverse transcriptase (hTERT) is a catalytic subunit of telomerase and is closely related to immortalization of cells, tumorigenesis and senescence of cells. hTERT has a great relationship with the occurrence and development of skin malignant tumors (melanoma, squamous cell carcinoma, basal cell carcinoma, cutaneous lymphoma, etc.). Abnormal expression of hTERT has important clinical application value in early diagnosis, individualized comprehensive treatment and prognosis evaluation of cutaneous malignant tumors. \u0000 \u0000Key words: \u0000Telomere; Skin neoplasms; Genes; Human telomerase reverse transcriptase","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"13 1","pages":"634-637"},"PeriodicalIF":0.0,"publicationDate":"2019-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75563643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}